This early study looked at a combination of two antibody drugs, talquetamab and teclistamab, for people with high-risk, relapsed multiple myeloma that has spread outside the bone marrow. The study did not report how many people were enrolled, but it followed them for about a year.
The main findings were that 79% of patients responded to the treatment, and 61% were free of cancer growth after 12 months. However, 31% had serious infections, and five treatment-related deaths were reported.
The study has important limits. It was a single-arm study with no direct comparison group, and the follow-up time was short. The results are only indirect comparisons to other treatments like CAR-T therapy.
Because of these limits, the findings are not practice-changing. They suggest this drug combination may be an option for some patients, but more research is needed to confirm safety and effectiveness before it can be widely recommended.